HUMA - Humacyte Inc Options
This article provides a detailed financial overview of Humacyte Inc. (HUMA), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS growth, insider and institutional ownership, profitability margins, and stock performance over different periods.
Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMAW
This article provides a brief financial overview for Humacyte, Inc. (NASDAQ: HUMAW), focusing on its enterprise value to revenue forward metric. The content highlights the company's stock market information and indicates a focus on financial data without elaborating on specific figures or analysis.
Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte Financial Disclosures & SEC Filings
This page provides access to Humacyte, Inc.'s SEC filings and other important company documents, including earnings reports, annual and quarterly reports, corporate presentations, and event transcripts. The documents span from 2026 back to 2023, offering detailed insights into the company's financial performance, operational updates, clinical trial results, and strategic initiatives related to products like Symvess and ATEV. It serves as a comprehensive resource for evaluating Humacyte's progress in vascular medicine, including trauma, dialysis, and coronary markets.
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why
Humacyte Inc.'s stock (HUMA) dropped by 2.32% on the last trading day, underperforming the broader market gains. Over the past month, the stock has fallen 44.9%. Analysts project positive earnings and revenue growth for the upcoming quarter, but the company currently holds a Zacks Rank of #3 (Hold).
Humacyte Announces $50 Million Public Offering of Common Stock
Humacyte Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company, has announced a $50 million public offering of common stock. Paul Hastings LLP advised Barclays, BTIG, and Titan Partners on the offering, while Covington & Burling LLP advised Humacyte Inc. Further details of the offering are restricted to Standard 1 Year members of Global Legal Chronicle.
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMA
This page from TradingView provides a financial overview for Humacyte, Inc. (NASDAQ: HUMA), specifically focusing on its price-to-earnings forward metric. The content highlights the company's stock market information and indicates no recent trades, suggesting the market was closed. It also lists various data providers contributing to the platform's financial information.
Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data
Humacyte's (HUMA) fair value estimate has significantly decreased from US$7.86 to US$2.05 following the V012 data release, reflecting split analyst views. While some analysts are bullish on the acellular vessel opportunity, others have trimmed expectations due to increased caution on execution, timelines, or valuation assumptions. This recalibration is driven by revised assumptions for long-term revenue growth, net profit margin, and P/E multiple.
Price to earnings forward of Humacyte, Inc. – BOATS:HUMA
This article provides financial information for Humacyte, Inc. (HUMA) on the TradingView platform, specifically focusing on its Price to Earnings Forward metric. The content highlights the company's stock symbol on the Blue Ocean Alternative Trade System (BOATS). The brief article primarily consists of navigation and platform information, with specific financial data for HUMA listed as "Period Value Change Change % Made by humans" without numerical details.
Enterprise value to revenue forward of Humacyte, Inc. – BOATS:HUMA
The article provides the enterprise value to revenue forward for Humacyte, Inc. (HUMA) on the Blue Ocean Alternative Trade System (BOATS:HUMA). It highlights that the market was closed at the time of publication, with no trades reported. The information is presented within the context of TradingView's financial data offerings.
Form 13G Humacyte For: 22 June By Investing.com
This article reports on a Form 13G filing for Humacyte (HUMA) on June 22. It is a brief announcement from Investing.com and includes financial data and various market indices, but no specific details about the filing itself. The article also contains a list of popular news and market movers.
Davidson Kempner reports 4.74% stake in Humacyte (NASDAQ: HUMA)
Davidson Kempner-affiliated entities have reported a 4.74% stake in Humacyte (NASDAQ: HUMA) through a Schedule 13G filing. This amounts to 12,787,073 shares, calculated based on 269,638,156 shares outstanding. Anthony A. Yoseloff is identified as responsible for the voting and investment decisions for this passive, below-control ownership.
Humacyte, Inc. (HUMA) dips more than broader market: What you should know
This article from MSN discusses that Humacyte, Inc. (HUMA) experienced a stock dip that was more significant than the broader market's decline. It suggests investors might want to investigate the reasons behind this underperformance.
Humacyte Inc (HUMA) Institutional Confidence
Humacyte Inc (HUMA) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 29.83% quarter-over-quarter to 32.47%. Fresenius SE & Co KGaA is the largest institutional shareholder with 18.31 million shares.
Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Humacyte Inc (HUMA) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $3.50 for HUMA, with individual targets ranging from $3.00 to $25.00. The company's expected revenue for the next quarter is $1.12 million, and most analysts recommend a "Buy" rating for its stock.
Humacyte Inc (HUMA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Humacyte Inc's (HUMA) dividend and stock split history.
Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Humacyte Inc (HUMA), focusing on its business segments, regional revenue, and profit contribution. It notes that relevant data for several fiscal quarters of FY2025 and FY2022 has not yet been disclosed by the company. The only specific data provided is a United States revenue of $2.04 million, with a 0.00% proportion, without further context.
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) experienced a 3.74% drop in its latest trading session, underperforming the S&P 500, while the Dow saw gains and the Nasdaq depreciated. Despite this, the company's shares have risen 19.1% over the past month. Analysts project significant increases in EPS and revenue for Humacyte's upcoming earnings report, and the stock currently holds a Zacks Rank of #2 (Buy).
Humacyte (HUMA) Barclays 28th Annual Global Healthcare Conference Summary
Humacyte (HUMA) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting the commercial progress of its vascular product, which has seen improved adoption after a price adjustment and increased focus on education. The company detailed positive clinical trial data, especially for dialysis access, and outlined its market strategy for trauma and dialysis, including efforts for CMS pass-through reimbursement. Humacyte also emphasized its relationship with Fresenius for global distribution.
Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results
Humacyte (NASDAQ:HUMA) announced positive Phase 3 V012 trial results for its bioengineered blood vessel (ATEV), demonstrating superiority over traditional AV fistulas for women on dialysis. The ATEV showed a significant increase in catheter-free days and a lower infection rate. Humacyte plans to file a supplemental Biologics License Application (sBLA) with the FDA in the second half of 2026 based on these results.
Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure
Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG disclosed an updated beneficial ownership of 18,312,735 shares, representing 6.8% of Humacyte's outstanding common stock. This percentage decreased from 8.4% not due to share disposition by Fresenius, but solely due to an increase in Humacyte's total outstanding shares to 269,638,156 as of June 12, 2026. The filing also noted Mollie Miller's appointment as VP and Assistant Treasurer of Fresenius Medical Care Holdings, Inc.
Bioengineered blood vessel helps women on dialysis avoid catheters longer
Humacyte's bioengineered blood vessel (ATEV) significantly outperformed the standard AV fistula in a Phase 3 study for women on dialysis, leading to more catheter-free days and fewer infections. The positive results support Humacyte's plan to file a supplemental Biologics License Application (BLA) with the FDA in the second half of 2026, targeting adult patients with end-stage kidney disease at high risk of AV fistula maturation failure. Despite strong clinical data, the company's stock has historically shown a mixed market response to such positive announcements.
Biotech Humacyte plans stock sale to fund Symvess dialysis push
Humacyte (Nasdaq: HUMA) has commenced an underwritten public offering of common stock, with proceeds intended to fund the commercialization of Symvess, a planned Biologics License Application supplement for hemodialysis, pipeline development, and general corporate purposes. The offering includes an option for underwriters to purchase up to an additional 15% of shares. Barclays, BTIG, and Titan Partners are acting as joint book-running managers.
Humacyte (HUMA) CEO indirectly awarded 80,000 stock options via spouse
Humacyte, Inc.'s President and CEO, Laura E. Niklason, was indirectly awarded 80,000 stock options through her spouse. These options have an exercise price of $1.08 per share and expire on June 11, 2036. The vesting schedule begins on June 11, 2027, with 25% exercisable then, followed by equal monthly installments until June 11, 2030.
Humacyte (HUMA) director receives 80,000 stock options at $1.08 exercise price
Humacyte, Inc. director Michael T. Constantino was granted 80,000 stock options at an exercise price of $1.08 per share, expiring on June 11, 2036. The options will vest over time, with the first 25% vesting on June 11, 2027, and the remainder vesting in equal monthly installments until June 11, 2030. This transaction was reported via a Form 4 SEC filing and is considered a neutral event for the stock.
Humacyte (HUMA) director receives 80,000 stock options at $1.08 strike price
Humacyte, Inc. director Max N. Wallace was granted 80,000 stock options with an exercise price of $1.08 per share, set to expire on June 11, 2036. The options will vest over time, with the first 25% becoming exercisable on June 11, 2027, and the remainder vesting monthly through June 11, 2030. This award is compensation-related and not an open-market transaction.
Director at Humacyte (NASDAQ: HUMA) receives 80,000 stock options grant
Humacyte, Inc. director Susan Richards Windham-Bannister received a grant of 80,000 stock options with an exercise price of $1.08 per share, expiring on June 11, 2036. The options will vest over time, with 25% exercisable on June 11, 2027, and the remainder vesting monthly until June 11, 2030. This grant increases her direct holdings to 80,000 stock options as a compensation-related acquisition.
[Form 4] Humacyte, Inc. Insider Trading Activity
Humacyte, Inc. director Kathleen Sebelius was granted 80,000 stock options, offering the right to purchase common stock at an exercise price of $1.08 per share. These options will vest over several years, with the first 25% exercisable on June 11, 2027, and the remainder vesting monthly until June 11, 2030, and will expire on June 11, 2036. This transaction is classified as a grant of derivative securities, not an open-market purchase or sale.
H.C. Wainwright raises Humacyte stock price target on trial data
H.C. Wainwright increased its price target for Humacyte Inc. (NASDAQ:HUMA) to $4.00 from $3.00, maintaining a Buy rating after the company reported positive interim results from its Phase 3 V012 study for Symvess. The trial showed statistically significant improvement in catheter-free days for patients with end-stage kidney disease. Humacyte also announced a public offering of common stock to raise $50 million and plans to file a supplemental biologics license application in the second half of 2026.
Humacyte (HUMA) prices 47.6M-share stock sale at $1.05 to fund Symvess
Humacyte (HUMA) has priced a public offering of 47,619,048 shares of common stock at $1.05 per share, aiming to raise $50 million in gross proceeds. The net proceeds, estimated at $46.80 million or up to $53.85 million if underwriters fully exercise their option, will primarily fund the commercialization of its Symvess product, support a Biologics License Application supplement for hemodialysis, and advance its pipeline and general corporate purposes. Barclays, BTIG, and Titan Partners are acting as joint book-running managers for the offering, which is expected to close around June 12, 2026.
Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M
Humacyte has entered into an underwriting agreement to sell 47,619,048 shares of common stock at $1.05 per share, expecting to net approximately $46.8 million. The underwriters, including Barclays Capital, BTIG, and Titan Partners Group, have a 30-day option to purchase an additional 7,142,857 shares. If the option is fully exercised, the net proceeds could reach about $53.85 million, with the offering expected to close around June 12, 2026.
Humacyte (NASDAQ: HUMA) priced 47.6M shares at $1.05; Phase 3 met endpoint
Humacyte (NASDAQ: HUMA) announced the pricing of an offering of 47.6 million shares of common stock at $1.05 per share, with an option for underwriters to purchase an additional 7.14 million shares. The offering is expected to yield approximately $47.0 million in net proceeds for the company, before expenses. This announcement follows positive top-line interim results from its V012 Phase 3 trial, where its ATEV met the primary endpoint by demonstrating superior catheter-free days compared to AV fistula, and the company plans to submit a supplemental Biologics License Application (BLA) in the second half of 2026.
Humacyte prices $50M public offering of common stock at $1.05/share
Humacyte, Inc. has announced the pricing of its public offering of 50,000,000 shares of common stock at $1.05 per share. The offering aims to raise gross proceeds of approximately $52.5 million before deductions for underwriting discounts and other expenses. Piper Sandler and Oppenheimer & Co. are acting as joint book-running managers for the offering.
Why Is Humacyte Stock Falling Thursday?
Humacyte's stock fell on Thursday despite reporting positive interim Phase 3 results for its acellular tissue-engineered vessel (ATEV) in dialysis patients. The decline was attributed to a heavily dilutive public offering of 47.6 million shares at $1.05 per share, generating $50 million, which overshadowed the successful clinical trial data demonstrating improved catheter-free days and a favorable safety profile for ATEV. The company plans to use the proceeds for commercialization, regulatory filings, and pipeline development.
Why is Humacyte stock sliding today?
Humacyte stock fell significantly after the company priced a $50 million public offering at a substantial discount, diluting existing shares. This dilution occurred despite positive interim Phase 3 study results for its ATEV product in female dialysis patients, which met its primary endpoint. The capital raised will fund the commercialization of its FDA-approved Symvess product and support a Biologics License Application filing.
Humacyte launches public offering of common stock
Humacyte Inc. has announced an underwritten public offering of its common stock, with underwriters having a 30-day option to purchase an additional 15% of shares. The biotechnology company plans to use the proceeds to fund the commercialization of Symvess, its FDA-approved product, support a Biologics License Application supplement for hemodialysis, advance pipeline product candidates, and for general corporate purposes. This follows a 45% year-to-date surge in its stock, positive Phase 3 results for its dialysis access product, and increased price targets from analysts.
Humacyte prices $50 million public offering at $1.05 per share
Humacyte, Inc. has announced the pricing of a $50 million public offering of 47,619,048 shares of common stock at $1.05 per share, below its current trading price. The biotechnology company intends to use the net proceeds to fund the commercialization of Symvess, develop product candidates, and for general corporate purposes, signaling a critical move to support its cash-burning operations and advance its recently FDA-approved product. This offering follows recent positive Phase 3 study results and an increased price target from Benchmark, highlighting the company's strategic advancements.
Biotech Humacyte prices $50M sale to fund Symvess, dialysis filing
Humacyte (Nasdaq: HUMA) has priced an underwritten public offering of 47,619,048 shares of common stock at $1.05 per share, aiming to raise approximately $50 million. The biotech company intends to use the net proceeds to commercialize Symvess, support a planned Biologics License Application supplement for a hemodialysis indication, advance pipeline candidates, and for general corporate purposes. This offering is projected to close around June 12, 2026, with underwriters having a 30-day option to purchase additional shares.
Humacyte, Inc. Announces Underwritten Public Offering of Common Stock
Humacyte, Inc. has announced an underwritten public offering of its common stock to secure funding for the commercialization of Symvess®, development of pipeline products, and general corporate purposes. Barclays, BTIG, and Titan Partners are acting as joint book-running managers for the offering, which is subject to market conditions. The company has filed a shelf registration statement with the SEC for this offering.
Humacyte reports positive Phase 3 trial results for dialysis access
Humacyte, Inc. announced positive interim Phase 3 trial results for its V012 study, which evaluates an acellular tissue engineered vessel (ATEV) for dialysis access in female patients. The study met its primary endpoint, showing significantly more catheter-free days for ATEV recipients compared to the standard autologous arteriovenous fistula. Investors reacted positively, with Humacyte's stock increasing, and the company plans to file a supplemental Biologic License Application with the FDA in the second half of 2026.
[8-K] Humacyte, Inc. Reports Material Event
Humacyte, Inc. announced positive interim Phase 3 results for its acellular tissue engineered vessel (ATEV) in female dialysis patients for arteriovenous access. The ATEV met the primary endpoint in the V012 study, demonstrating 91 more catheter-free days than autologous arteriovenous fistula, with significantly lower infection rates. The company plans to file a supplemental Biologic License Application with the FDA in the second half of 2026 for high-risk end-stage kidney disease patients based on these findings.
Humacyte Announces Positive Interim Results for V012 Phase 3 Clinical Trial of Acellular Tissue Engineered Vessel in Female Dialysis Access Patients
Humacyte, Inc. announced positive interim results from its Phase 3 V012 clinical trial for its acellular tissue engineered vessel (ATEV) in female dialysis patients, meeting the primary endpoint of superior catheter-free days compared to standard care (AV fistula). ATEV patients experienced significantly more catheter-free days and fewer access infections, demonstrating a favorable safety profile. Humacyte plans to file a supplemental Biologic License Application with the FDA in the second half of 2026 based on these findings.
[424B5] Humacyte, Inc. Prospectus Supplement (Debt Securities)
Humacyte, Inc. has filed a preliminary prospectus supplement for an offering of common stock to fund the commercialization of Symvess, a planned supplemental BLA filing for hemodialysis, pipeline development, and working capital. The company announced positive interim results from its V012 Phase 3 trial, showing improved catheter-free days and lower infection rates for ATEV patients compared to AV fistula. Despite these positive clinical results, Humacyte disclosed substantial doubt about its ability to continue as a going concern without additional financing, as current resources are projected to fund operations only into the first quarter of 2027.
Humacyte stock falls 6% on public offering announcement
Humacyte Inc. shares dropped 6% in after-hours trading following the announcement of an underwritten public offering of common stock. The company plans to use the net proceeds to fund the commercialization of Symvess, its first FDA-approved product, support a Biologics License Application supplement filing, develop pipeline product candidates, and for general corporate purposes. Barclays, BTIG, and Titan Partners are serving as joint book-running managers for the offering.
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
Humacyte, Inc. announced a proposed underwritten public offering of its common stock, with the intention to grant underwriters a 30-day option to purchase an additional 15% of the shares. The company plans to use the net proceeds for commercialization of Symvess®, BLA filing for hemodialysis, pipeline development, and general corporate purposes. Barclays, BTIG, and Titan Partners are acting as joint book-running managers for the offering.
Humacyte (NASDAQ: HUMA) holders OK share boost, pay and auditor
Humacyte, Inc. shareholders approved several key proposals at their 2026 Annual Meeting, including increasing authorized common shares from 350 million to 550 million. They also elected three Class II directors, gave advisory approval to executive compensation, opted for annual "say-on-pay" votes, and ratified PricewaterhouseCoopers LLP as their independent auditor. These actions demonstrate shareholder support for the company's governance, compensation framework, and financial oversight, while providing Humacyte with increased flexibility for future capital strategies.
HUMA: All proposals, including director elections and share increase, passed with strong support
All proposals at Humacyte, Inc.'s 2026 AGM, including director elections, executive compensation, auditor ratification, and an increase in authorized shares, passed with strong support. No questions were raised by stockholders during the session. This summary is based on the AGM audio transcript.
Humacyte, Inc. Files Form 8-K with SEC: Company Details, Stock Information, and Regulatory Disclosures
Humacyte, Inc. has filed an 8-K with the SEC regarding a Nasdaq compliance notification. The company's common stock had previously fallen below the minimum bid price of $1.00 for 30 consecutive business days, triggering a compliance review. While currently compliant and listed on Nasdaq under HUMA and HUMAW, the filing emphasizes the need for continued shareholder vigilance regarding the company's ability to maintain the minimum bid price requirement to avoid delisting.
Humacyte (NASDAQ: HUMA) back in line with Nasdaq $1.00 bid rule
Humacyte (NASDAQ: HUMA) has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company received notification on June 5, 2026, that its common stock had closed at or above the $1.00 threshold for at least 10 consecutive business days, resolving the previous non-compliance issue that arose when its stock traded below $1.00 for 30 consecutive days ending May 1, 2026. This action removes the immediate risk of delisting from The Nasdaq Global Select Market.
Humacyte regains Nasdaq $1.00 bid-price compliance after May deficiency
Humacyte (HUMA) has regained compliance with Nasdaq's minimum $1.00 bid-price requirement. The company had previously received a deficiency notice in May 2026 after its share price closed below $1.00 for 30 consecutive business days. Nasdaq confirmed Humacyte's compliance on June 5, 2026, closing the matter.
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Humacyte, Inc. (NASDAQ: HUMA) breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to contact the firm to discuss potential corporate governance reforms, recovery of funds, or other benefits. The firm operates on a contingent fee basis, and shareholder participation is highlighted as beneficial for improving company transparency and value.
